Patient Compliance and its Impact on Steady State Pharmacokinetics

  • Wenping Wang


Physicians commonly prescribe drug products in a multiple dosage regimen (e.g., one daily or q.d., twice daily or b.i.d, etc.) for prolonged therapeutic activity. The purpose of a multiple dose regimen is to maintain the drug plasma concentration within its therapeutic window (i.e., the concentration of drug in the serum or plasma should yield optimal benefit at a minimal risk of toxicity). To study the effect of multiple dosing on drug concentration in blood, researchers often employ a deterministic model with the assumptions that drugs are administered at a fixed dosage, with fixed (usually constant) dosing intervals. In practice, as is well known in the medical community, patients may not follow such a rigid schedule. Hence, two possible scenarios might occur: patients might not take the prescribed dosage, resulting in irregular dosing amounts; or they might not adhere to the dosing schedule, resulting in irregular dosing times. This chapter intends to lay out a probability framework to model these two types of noncompliance and consequently study their impact on the steady state pharmacokinetics in a rigorous setting.


Markov Chain Model Dose Time Steady State Pharmacokinetic Multiple Dose Regimen Trough Concentration Series 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cramer, J., Mattson, R., Prevey, M., Scheyer, R., and Ouellette, V. (1989). How often is medication taken as prescribed?. Journal of the American Medical Association 261, 3273–3277.CrossRefGoogle Scholar
  2. Evans, W., Schentag, J., and Jusko, W., eds. (1986). Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Applied Therapeutics, Vancouver, WA.Google Scholar
  3. Gibaldi, M., and Perrier, D. (1975). Pharmacokinetics. Marcel Dekker, New York.Google Scholar
  4. Girard, P. Sheiner, L., Kastrisios, H., and Blaschke, T. (1996). Do we need full compliance data for population pharmacokinetic analysis?. Journal of Pharmacokinetics and Biopharmaceutics 24(3) 265–282.Google Scholar
  5. Glanz, K., Fiel, S., Swartz, M., and Francis, M. (1984). Compliance with an experimental drug regimen for treatment of asthma: its magnitude, importance, and correlates. Journal of Chronic Disease 37, 815–824.CrossRefGoogle Scholar
  6. Kastrisios, H., Suares, J., Flowers, B., and Blaschke, T. (1995). Could decreased compliance in an aids clinical trial affect analysis of outcomes?. Clinical Pharmacology and Therapeutics 57, 190–198.Google Scholar
  7. Lim, L. (1992). Estimating compliance to study medication from serum drug levels: Application to an aids clinical trial of zidovudine. Biometrics 48, 619–630.CrossRefGoogle Scholar
  8. Mitenko, P., and Oglivie, R. (1973). Pharmacokinetics of intravenous theo- phylline. Clinical Pharmacology and Therapeutics 14, 509–513.Google Scholar
  9. Ritschel, W. (1986). Handbook of Basic Pharmacokinetics. 3rd ed. Drug Intelligence Publications.Google Scholar
  10. Thron, C. (1974). Linearity and superposition in pharmacokinetics. Pharmacology Review 26 (1), 3–31.MathSciNetGoogle Scholar
  11. Wagner, J. (1975). Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications.Google Scholar
  12. Wang, W., and Ouyang, S. (1998). The formulation of the principle of superposition in the presence of non-compliance and its applications in multiple dose pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 26 (4), 457–469.Google Scholar
  13. Wang, W., Hsuan, F., and Chow, S. (1996). The impact of patient compliance on drug concentration profile in multiple dose. Statistics in Medicine 15, 659–669.CrossRefGoogle Scholar
  14. Weinberger, M., Hendeles, L., and Bighley, L. (1978). The relation of product formulation to absorption of oral theophylline. New England Journal of Medicine 299, 852–857.CrossRefGoogle Scholar
  15. Weinberger, M., Hendeles, L., Wong, L., and Vaughan, L. (1981). Relationship of formulation and dosing interval to fluctuation of serum theophylline concentration in children with chronic asthma. Journal of Pediatrics 99, 145–152.CrossRefGoogle Scholar
  16. Weiss, M., and Förster, W. (1979). Pharmacokinetic model based on circulatory transport. European Journal of Clinical Pharmacology 16, 287–293.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Wenping Wang
    • 1
  1. 1.Pharsight CorporationCaryUSA

Personalised recommendations